Gland Pharma share price
NSE: GLANDBSE: 543245Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 23 Oct 2026. Previous close ₹2,850.40.
- Next results date: the board meets on 6 Nov 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹46,645 Cr261st largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 10 Aug 2026
- 41.3
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 15 May 2026
- 4.5
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.71%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 10 Aug 2026
- 11.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 10 Aug 2026
- 12.4%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 15 May 2026
- 0.02
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 4,23,05755.6% delivered
Results
Consolidated; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Jun 2026, against the quarter beforeFiled 10 Aug
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹1,800 Crup 3.30%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹317 Crdown 13.56%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- 17.6%
Revenue by year
Net profit by year, a loss in red
| ₹ crore | Sep 2024Filed 4 Nov | Dec 2024Filed 3 Feb | Mar 2025Filed 12 Jun | Jun 2025Filed 5 Aug | Sep 2025Filed 3 Nov | Dec 2025Filed 28 Jan | Mar 2026Filed 15 May | Jun 2026Filed 10 Aug |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1,406 | 1,384 | 1,425 | 1,506 | 1,487 | 1,695 | 1,743 | 1,800 |
| Net profit | 164 | 205 | 187 | 215 | 184 | 261 | 367 | 317 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 11.6% | 14.8% | 13.1% | 14.3% | 12.4% | 15.4% | 21.0% | 17.6% |
Business segments
In the year to Mar 2026 the company reports one business segment, Pharmaceuticals, which carries all its revenue.
Valuation
Today, against the company's own history.PE ratio and valuation history
At or below today's level on 62% of 1,240 trading days over the last 5 years.
At or below today's level on 76% of 1,240 trading days over the last 5 years.
At or below today's level on 73% of 1,240 trading days over the last 5 years.
At or below today's level on 60% of 1,240 trading days over the last 5 years.
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | +7.7% | +47.1% | −27.6% | 1.2% |
| 3 years | +11.3% | +9.5% | +0.6% | 1.1% |
| 5 years | −6.6% | +0.5% | −7.7% | 0.7% |
Mutual funds holding it
169 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 61 of the 93 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future.Mutual fund holdings
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 12
- Bought againBought again. Funds that held it at the month's end, had not held it the month before, and held it in an earlier month.
- 14
- AddedAdded. Funds that held more shares than at the end of the month before.
- 40
- CutCut. Funds that held fewer shares than at the end of the month before.
- 53
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 50
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end.
- 5
| Fund | |||
|---|---|---|---|
 HDFC Mid Cap FundHDFC Mutual Fund | 60,67,814 | 1.73% | ₹1,759.3 Cr |
 Kotak Mid Cap FundKotak Mahindra Mutual Fund | 36,65,817 | 1.60% | ₹1,062.9 Cr |
 SBI Large & Midcap FundSBI Mutual Fund | 31,86,587 | 2.28% | ₹923.9 Cr |
 Nippon India Growth Mid Cap FundNippon India Mutual Fund | 28,00,000 | 1.62% | ₹811.8 Cr |
| Nippon India Small Cap FundNippon India Mutual Fund | 18,32,424 | 0.66% | ₹531.3 Cr |
 Mirae Asset Large & Midcap FundMirae Asset Mutual Fund | 16,94,152 | 1.15% | ₹491.2 Cr |
| HDFC Large & Mid Cap FundHDFC Mutual Fund | 14,00,000 | 1.42% | ₹405.9 Cr |
 DSP Small Cap FundDSP Mutual Fund | 13,15,806 | 1.78% | ₹381.5 Cr |
 Axis Small Cap FundAxis Mutual Fund | 12,87,862 | 1.22% | ₹373.4 Cr |
 ICICI Prudential India Opportunities FundICICI Prudential Mutual Fund | 12,63,529 | 1.00% | ₹366.3 Cr |
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Gland Pharma in market cap.
Where the company sits among the companies nearest its size
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 Alkem LaboratoriesALKEM | 59,149 | 27.4 | 4.3 | 19.5 | +13.4% | −5.6% | 16.7% | 16.5% | 1.07% |
 Abbott IndiaABBOTINDIA | 53,187 | 32.9 | 11.1 | 25.9 | +6.3% | +11.2% | 35.9% | 39.6% | 2.62% |
 BioconBIOCON | 52,721 | 106.4 | 1.5 | 18.2 | +9.8% | +28.6% | 1.8% | 2.9% | 0.15% |
 IPCA LaboratoriesIPCALAB | 49,556 | 37.8 | 6.1 | 22.3 | +10.6% | +68.2% | 17.4% | 17.6% | 0.31% |
 Ajanta PharmaAJANTPHARM | 41,035 | 36.2 | 9.1 | 28.0 | +20.2% | +22.0% | 27.3% | 27.2% | 1.83% |
 GlaxoSmithKline PharmaceuticalsGLAXO | 40,737 | 38.1 | 18.0 | 29.1 | +5.8% | +12.4% | 50.6% | 56.3% | 2.37% |
 Emcure PharmaceuticalsEMCURE | 33,586 | 33.2 | 6.8 | 17.5 | +18.4% | +35.9% | 21.5% | 25.2% | 0.20% |
 Sai Life SciencesSAILIFE | 29,639 | 81.9 | 11.9 | 45.0 | – | – | 15.7% | 18.7% | 0.00% |
Dividends
Per share, by the year it was paid for, and the latest payments.Dividend history and dates
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up.| Ex-date | Type | Per share |
|---|---|---|
| 11 Aug 2026 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹20.00 |
| 14 Aug 2025 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹18.00 |
| 16 Aug 2024 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹20.00 |
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
21 Oct · Analysts
6 Oct · Meeting
1 Oct · Management
1 Oct · Board meeting
Gland Pharma share price by year
Each calendar year to 2025.Gland Pharma share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 1,722.00 | −3.2% | 2,102.10 | 1,392.80 |
| 2024 | 1,779.35 | −7.5% | 2,141.60 | 1,605.85 |
| 2023 | 1,924.50 | +22.1% | 1,947.20 | 893.55 |
| 2022 | 1,576.55 | −59.2% | 3,981.05 | 1,573.35 |
| 2021 | 3,864.55 | +65.2% | 4,316.25 | 2,078.10 |
| 2020 | 2,339.75 | – | 2,408.35 | 1,819.55 |
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on NSE.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 23 Oct 2026 | 2,848.90 | 2,924.00 | 2,769.80 | 2,826.80 | 2,814.43 | 4,23,057 | 55.6% |
| 22 Oct 2026 | 2,906.10 | 2,953.90 | 2,829.00 | 2,850.40 | 2,884.47 | 3,38,424 | 55.4% |
| 21 Oct 2026 | 3,005.10 | 3,028.30 | 2,839.60 | 2,935.00 | 2,911.47 | 12,03,469 | 60.7% |
| 19 Oct 2026 | 3,046.10 | 3,075.10 | 3,002.80 | 3,019.80 | 3,038.33 | 1,67,122 | 55.5% |
| 16 Oct 2026 | 3,096.90 | 3,096.90 | 3,004.30 | 3,043.40 | 3,028.69 | 1,65,156 | 48.0% |
| 15 Oct 2026 | 3,040.20 | 3,076.90 | 3,000.10 | 3,066.30 | 3,047.46 | 1,56,231 | 53.7% |
| 14 Oct 2026 | 3,099.00 | 3,105.00 | 3,042.00 | 3,052.30 | 3,055.18 | 1,78,927 | 56.4% |
| 13 Oct 2026 | 3,078.40 | 3,105.00 | 3,040.00 | 3,091.10 | 3,076.46 | 2,07,496 | 62.4% |
| 12 Oct 2026 | 3,070.00 | 3,095.90 | 3,025.00 | 3,078.40 | 3,063.54 | 2,11,881 | 54.1% |
| 9 Oct 2026 | 3,059.10 | 3,121.90 | 3,008.20 | 3,061.80 | 3,067.94 | 1,81,216 | 37.2% |
About Gland Pharma
Gland Pharma Limited makes sterile injectable medicines. It sells them to other pharmaceutical companies under a business-to-business (B2B) model built on long-term partnerships. Its products serve therapeutic areas that include oncology, ophthalmology and central nervous system disorders. Products it supplies include Enoxaparin, Vancomycin, Chlorothiazide, Heparin and Daptomycin.
The company reports its business in two parts: B2B, and CDMO. A CDMO, or contract development and manufacturing organisation, develops and makes medicines for other companies under contract. Both parts sell into the United States, Europe, India, and Canada, Australia and New Zealand, along with other countries.
In India, it operates four formulation manufacturing facilities, in Hyderabad and at a special economic zone in Visakhapatnam. Its European business, Cenexi, operates four more in France and Belgium. The Indian sites have lines for vials, ampoules, pre-filled syringes, infusion bags and ophthalmic products, and for cartridges. The Dundigal site, a 5,00,000 sq. ft. sterile injectable facility, was approved by the United States drug regulator in 2003. The Pashamylaram site, of 6,00,000 sq. ft., began operations in July 2015. As of June 2026, the company has made 389 filings with the United States drug regulator for generic medicines, known as ANDAs, of which 342 are approved.
The company was founded in Hyderabad, where its registered office remains. It was incorporated in 1978. It acquired Cenexi to strengthen its CDMO platform.
- Legal name
- Gland Pharma Limited
- NSE symbol
- GLAND
- BSE code
- 543245
- ISIN
- INE068V01023
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Nov 2020
- Face value
- ₹1
- CIN
- L24239TG1978PLC002276
- Corporate identity number, the registrar of companies' code for it